Evidence map›Paper›PMID 32903548›Full record

ArticleFrontiers in bioengineering and biotechnology2020

Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications.

Sandra Pacharra, Seán McMahon, Patrick Duffy, Pooja Basnett, Wenfa Yu, Sabine Seisel, Ulrik Stervbo, Nina Babel, Ipsita Roy, Richard Viebahn and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Application of PLCL as a biodegradable polymer in biomedical engineering.Journal of materials science. Materials in medicine · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Frontiers in bioengineering and biotechnology · 2024
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Sandra PacharraSalber Laboratory, Centre for Clinical Research, Department of Experimental Surgery, Ruhr-Universität Bochum, Bochum, Germany.
Seán McMahonLaboratory A, Synergy Centre, Ashland Specialties Ireland Ltd., Dublin, Ireland.
Patrick DuffyLaboratory A, Synergy Centre, Ashland Specialties Ireland Ltd., Dublin, Ireland.
Pooja BasnettSchool of Life Sciences, College of Liberal Arts and Sciences, University of Westminster, London, United Kingdom.
Wenfa YuRosenhahn Group, Faculty of Chemistry and Biochemistry, Analytical Chemistry - Biointerfaces, Ruhr-Universität Bochum, Bochum, Germany.
Sabine SeiselFaculty of Chemistry and Biochemistry, Analytical Chemistry - Center for Electrochemical Sciences, Ruhr-Universität Bochum, Bochum, Germany.
Ulrik StervboCentre for Translational Medicine, Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.
Nina BabelCentre for Translational Medicine, Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.
Ipsita RoyRoy Group, Kroto Innovation Centre, Department of Materials Science and Engineering, University of Sheffield, Sheffield, United Kingdom.
Richard ViebahnDepartment of Surgery, Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH, Bochum, Germany.
Wenxin WangThe Charles Institute of Dermatology, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.
Jochen SalberSalber Laboratory, Centre for Clinical Research, Department of Experimental Surgery, Ruhr-Universität Bochum, Bochum, Germany.
Ruhr University Bochum · DEUniversitätsklinikum Knappschaftskrankenhaus Bochum · DEUniversitätsklinik Marien Hospital Herne · DEUniversity College Dublin · IEUniversity of Sheffield · GBUniversity of Westminster · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the use of bioresorbable materials in stent production is thought to improve long-term safety compared to their durable counterparts, a recent FDA report on the 2-year follow-up of the first FDA-approved bioresorbable vascular stent showed an increased occurrence of major adverse cardiac events and thrombosis in comparison to the metallic control. In order to overcome the issues of first generation bioresorbable polymers, a series of polyethylene glycol-functionalized poly-L-lactide-co-ε-caprolactone copolymers with varying lactide-to-caprolactone content is developed using a novel one-step PEG-functionalization and copolymerization strategy. This approach represents a new facile way toward surface enhancement for cellular interaction, which is shown by screening these materials regarding their cyto- and hemocompatibility in terms of cytotoxicity, hemolysis, platelet adhesion, leucocyte activation and endothelial cell adhesion. By varying the lactide-to-caprolactone polymer composition, it is possible to gradually affect endothelial and platelet adhesion which allows fine-tuning of the biological response based on polymer chemistry. All polymers developed were non-cytotoxic, had acceptable leucocyte activation levels and presented non-hemolytic (<2% hemolysis rate) behavior except for PLCL-PEG 55:45 which presented hemolysis rate of 2.5% ± 0.5. Water contact angles were reduced in the polymers containing PEG functionalization (PLLA-PEG: 69.8° ± 2.3, PCL-PEG: 61.2° ± 7.5) versus those without (PLLA: 79.5° ± 3.2, PCL: 76.4° ± 10.2) while the materials PCL-PEG550, PLCL-PEG550 90:10 and PLCL-PEG550 70:30 demonstrated best endothelial cell adhesion. PLLA-PEG550 and PLCL-PEG550 70:30 presented as best candidates for cardiovascular implant use from a cytocompatibility perspective across the spectrum of testing completed. Altogether, these polymers are excellent innovative materials suited for an application in stent manufacture due to the ease in translation of this one-step synthesis strategy to device production and their excellent

Indexed as

bioresorbablecytocompatibilitypolyethylene glycolpoly-L-lactidepoly-ε-caprolactone

Identifiers

PMID32903548
PMCPMC7438451
OpenAlexW3049743017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.